PLANet 2'0 AHCC12 and AHCC13
Find out about the PLANet 2.0 study, which uses precision medicine to improve liver cancer treatment across the Asia-Pacific region.
Trial summary of AHCC 12 and AHCC 13
AHCC12 & AHCC13 | Precision Medicine in Liver Cancer across an Asia Pacific Network 2.0 (PLANet 2.0) (NCT05516628) AHCC12: Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)(EMPHASIS)(NCT05516628) AHCC13: Liquid Biopsy based Identification of Predictive Biomarkers of Response in Intermediate/Locally Advanced HCC receiving Y90 +/- Atezolizumab plus Bevacizumab (NCT05377034) |
|---|---|
Status | Recruiting |
Contributing Principal Investigators and Centres | Singapore Adrian Chiow (Changi General Hospital), Toh Han Chong (National Cancer Centre), Chee Cheng Ean (National University Hospital), Kam Juinn Huar (Sengkang General Hospital), Brian Goh (Singapore General Hospital), Samol Jens (Tan Tock Seng Hospital) Up to 11 overseas sites in Asia-Pacific |
Thematic Principal Investigators | Theme 1: Deep Phenotyping and Correlation with Clinical Responses to Therapy Name: Pierce Chow Name: Patrick Tan Theme 2: Elucidating Spatial Distribution of Biomarkers at Single-cell Resolution Name: Vinay Tergaonkar Theme 3: Translational and Functional Immunomics Name: Toh Han Chong Theme 4: Pre-Clinical Disease Modelling and Target Discovery Name: Tam Wai Leong Name: Polly Chen Theme 5: Data Architecture, Data Security and Data Science Applications Name: Liu Nan |
Protocol Chair | Pierce Chow |